Phase
Condition
N/ATreatment
IlluminOss Device
Clinical Study ID
Ages > 50 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Patient has been deemed a candidate for the IlluminOss device
Patient is male or non-pregnant female
Patient is willing and able to comply with the postoperative scheduled clinical andradiographic evaluations
Patient is willing and able to give informed consent if required
Traumatic patient is over the age of 50
IlluminOss procedure is the initial procedure to treat the traumatic injury
Exclusion
Exclusion Criteria:
United States (U.S.)
This product is contraindicated in U.S. patients who have:
an active or incompletely treated infection that could involve the site where thedevice will be implanted;
are allergic to any of the implant materials or to dental glue;
have an intramedullary canal measuring smaller than the diameter of the deliverysheath provided at the site of the fracture;
distant foci of infections which may spread to the implant site, have open fractureswith severe contamination;
or in patients for whom delivery sheath is unable to cross fracture site afterproper fracture reduction and realignment.
European Union (EU)
This product is contraindicated in EU patients who have:
For all Bones:
Patients who are considered skeletally immature.
Presence of active or incompletely treated infections that could involve the sitewhere the device will be implanted.
Patients allergic to any of the implant materials, or to dental glue.
Patients whose intramedullary canal at site of fracture measures smaller than thediameter of the sheath provided.
Uncooperative patient or patient with neurologic disorder, incapable of followingdirections.
Distant foci of infections which may spread to the implant site.
Vascular insufficiency.
Open fractures with severe contamination.
Extremely comminuted fractures where insufficient holding power of the balloon onthe intramedullary canal is probable.
Delivery sheath is unable to cross fracture site after proper fracture reduction andrealignment. For acute Humerus fractures:
Patients who are under the age of Fifty (50) For all bones excluding pathologic Humerus:
Metabolic disorders which may impair bone formation.
Osteomalacia.
Vascular insufficiency, muscular atrophy, or neuro-muscular disease.
Study Design
Study Description
Connect with a study center
St Vinzenz Hospital
Cologne,
GermanyActive - Recruiting
Johannes Wesling Hospital Minden
Minden,
GermanyActive - Recruiting
Petrus Hospital
Wuppertal,
GermanyActive - Recruiting
Gulf Orthopedics
Mobile, Alabama 36604
United StatesSite Not Available
Cedars-Sinai Medical Center
Los Angeles, California 90048
United StatesActive - Recruiting
Presbyterian St Luke's Medical Ctr
Denver, Colorado 80218
United StatesActive - Recruiting
University of Miami Hospital
Miami, Florida 33136
United StatesActive - Recruiting
Weston Outpatient Surgical Center
Weston, Florida 33326
United StatesActive - Recruiting
Parkview Health
Fort Wayne, Indiana 46845
United StatesActive - Recruiting
Jacobi Medical Center
Bronx, New York 10461
United StatesActive - Recruiting
Mission Hospital
Asheville, North Carolina 28801
United StatesSite Not Available
Wake Forest Baptist Health
Winston-Salem, North Carolina 27157
United StatesActive - Recruiting
Temple University Hospital
Philadelphia, Pennsylvania 19140
United StatesSite Not Available
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania 15232
United StatesActive - Recruiting
Ortho Rhode Island
Wakefield, Rhode Island 02879
United StatesActive - Recruiting
Memorial Hermann Hospital
Katy, Texas 77494
United StatesActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.